AIM Immunotech Inc. (AIM) - 10-K Filing Summary
Business Context and Reporting Period
Company: AIM Immunotech Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: AIM is an immuno-pharma company focused on developing Ampligen (rintatolimod), a double-stranded RNA molecule, primarily for the treatment of late-stage pancreatic cancer. The company also holds Alferon N Injection, an FDA-approved natural alpha-interferon for genital warts, though commercial sales are currently halted due to inventory shortages. Ampligen is approved for sale in Argentina for Chronic Fatigue Syndrome (CFS) but faces commercialization delays due to local economic conditions.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenues | $88,000 | $170,000 |
| Net Loss | ($13,958,000) | ($17,320,000) |
| Net Loss Per Share | ($8.62) | ($30.92) |
| Cash & Cash Equivalents | $2,985,000 | $1,701,000 |
| Total Assets | $5,782,000 | $8,608,000 |
| Total Liabilities | $15,565,000 | $9,930,000 |
| Stockholders' Deficit | ($9,783,000) | ($1,322,000) |
| Working Capital Deficit | ($2,929,000) | ($5,359,000) |
Note: Revenue is derived primarily from the Ampligen Cost Recovery Program. The company has no material commercial revenue.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $3.4 million (19%) compared to 2024. This improvement was driven by a $6.0 million decrease in General and Administrative (G&A) expenses and a $2.3 million decrease in Research and Development (R&D) expenses.
- Non-Recurring Income: Interest and other income included a $3.04 million gain from the settlement of disputed legal fees, where $3.04 million of previously billed fees were forgiven in exchange for a reduced payment.
- Warrant Liability: A significant loss of $3.98 million was recognized due to the issuance of Class E and Class F warrants, which were classified as liabilities under ASC 480. This created a warrant liability of $8.24 million on the balance sheet.
- Expense Reductions: G&A expenses dropped significantly due to reduced legal and consulting fees following the resolution of stockholder nomination litigation. R&D expenses decreased due to lower clinical trial and salary costs, partially offset by increased patent expenses.
Guidance, Outlook, and Risks
Strategic Focus: Management has decided to focus efforts on developing Ampligen for late-stage pancreatic cancer, viewing it as the most lucrative opportunity. The company is advancing the "DURIPANC" Phase 2 study combining Ampligen with AstraZeneca's Imfinzi. A Phase 3 trial design agreement was signed with Thermo Fisher Scientific in March 2026.
Liquidity and Going Concern: The filing includes a "Going Concern" warning. The company has a history of losses, a working capital deficit, and a stockholders' deficit of approximately $9.8 million. Management states that without successful capital raising, the company may be unable to continue operations for one year from the issuance date.
Listing Compliance: AIM is not in compliance with NYSE American listing requirements regarding minimum stockholders' equity ($6 million required; company has a $9.8 million deficit). A plan to regain compliance by June 11, 2026, has been accepted by the Exchange. Failure to comply could result in delisting.
Subsequent Events (Post-Dec 31, 2025):
- Stock Dividend: A 1-for-1,000 stock dividend was issued in January 2026, resetting Class E and F warrant terms and potentially allowing reclassification from liability to equity.
- Rights Offering: A rights offering completed in March 2026 raised approximately $1.8 million in gross proceeds.
- Warrant Exercises: Significant exercises of Class E and F warrants occurred in early 2026.
Key Risks:
- Substantial doubt about ability to continue as a going concern.
- Potential delisting from NYSE American if equity requirements are not met.
- Dependence on additional financing which may not be available or may be dilutive.
- Regulatory approval risks for Ampligen in the U.S.
Investor Verification Checklist
- Capital Adequacy: Verify the status of the June 11, 2026, deadline to regain NYSE American compliance and the specific capital raise mechanisms planned.
- Warrant Reclassification: Confirm the accounting treatment of Class E and F warrants following the January 2026 stock dividend and whether they have been reclassified from liability to equity, which would significantly improve the balance sheet.
- Clinical Trial Progress: Monitor enrollment and interim data release for the DURIPANC Phase 2 pancreatic cancer study, which is critical for future valuation and partnership potential.
- Legal Settlements: Review the final status of the legal fee settlement and any remaining contingent liabilities from prior litigation (e.g., Jorgl, Kellner, BioLife cases).
- Debt Maturity: Assess the repayment schedule for the Streeterville Capital notes, with significant portions due in 2026, and the company's ability to service this debt without further dilution.